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Background: Few studies have examined the differential impact of sublobar resection (SL) and lobectomy
(L) on quality of life (QoL) during the first postoperative year.
Methods: We used a prospective cohort of Stage IA lung cancer patients undergoing video-assisted
thoracoscopic surgery (VATS) from the Initiative for Early Lung Cancer Research on Treatment. QoL was
measured before surgery, and within 4, 6, and 12 months post-surgery using three validated instruments:
SF-12 [physical (PCS) and mental health (MCS)], FACT-LCS (lung-cancer-symptoms), and the PHQ-4
(anxiety and depression subscales). Locally weighted smoothing curve (LOWESS) was fitted to identify the
best interval knot for the change in the QoL trend post-surgery. After adjusting for demographic and clinical
variables, an adjusted piecewise linear mixed effects model was developed to estimate differences in baseline
and 12-month scores, and rates of change for each QoL measure.
Results: SL resection was performed in 127 (63.2%) and L in 74 (36.8%) patients. LOWESS plots
suggested that the shift of QoL (interval knot) was at 2 months post-surgery. Decreases in PCS scores
were less severe for SL than L patients 2 months post-surgery (−0.18 vs. −2.30, P=0.02); while subsequent
improvements were observed for both groups (SL: +0.29 vs. L: +0.74, P=0.06). SL patients reported
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significantly better scores a year post-surgery compared to baseline (P=0.003), while L patients did not.
Anxiety decreased at similar rates for both SL and L patients within 2 months post-surgery (P=0.18), then
stabilized for the remaining months. MCS and depression scores remained stable in both groups throughout.
QoL scores were lower for women than for men, but only significantly worse for the lung-cancer-symptoms
(P=0.003) and anxiety (P=0.04).
Conclusions: SL patients fared better in physical health and lung cancer symptoms than L patients. The
first two postoperative months showed the most significant change which suggests targeting postoperative
intervention during that time.
Keywords: Lung neoplasms; thoracic surgical procedures; quality of life; thoracoscopy; thoracic surgery; videoassisted
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Introduction
Introduction of CT screening has increased the frequency
of early stage lung cancer diagnoses, and thus also the
number of long-term lung cancer survivors. Concurrently,
treatment choices have also expanded to include important
technologic advancements in surgery and radiotherapy and
immunotherapy. To provide guidance to treating physicians,
ongoing randomized trials are comparing alternative
surgical approaches (1,2) and surgery with stereotactic
radiotherapy (3-6) for non-small cell lung cancer (NSCLC).
Prior to completion of these trials, and even upon their
completion, treating physicians and their patients are
faced with choosing a treatment that is personalized to
the particular patient’s situation. Physicians are involving
their patients in this decision-making process, as patientcentered elements must be considered prior to deciding on
treatment.
In 2014, focus groups were held separately with thoracic
surgeons and early stage surgical lung cancer survivors (7).
The qualitative analysis of the focus groups suggested that
surgeons prioritized clinical indicators to decide on the
best surgical approach and the extent of surgical resection,
whereas patients focused on the long-term consequences of
their surgery and wanted to better understand their options
and the resulting consequences on their survival and quality
of life (QoL) after surgery. The patients expressed feelings
of isolation, anxiety, and persistent and pervasive pain,
previously not well recognized. These results underscore
the need for increased focus on minimizing morbidity of
treatment and maximizing QoL.
A systematic review found that, while a body of literature
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on QoL after treatment for NSCLC is emerging (8), few
studies focused on early stage lung cancer (9-16). This
review coupled with the results of the focus groups led us to
an investigation of QoL scores, using Short Form 12, which
had been collected on early stage lung cancer patients by the
International Early Lung Cancer Action Program since 2001
(9,10). A comparison of pre- and post-surgical QoL scores
of Stage IA NSCLC patients diagnosed by CT screening
found a significant decrease in physical health scores
from pre- to one year after surgery among lobectomy (L)
patients but not among sublobar resection (SL) patients (9).
When the authors examined the effect of two surgical
approaches [video-assisted thoracoscopic surgery (VATS)
vs. traditional open chest thoracotomy], they found no
significant difference between the pre and post-surgical
scores of overall physical health or mental health (10).
In 2016, a prospective cohort study of documented
Stage I NSCLC patients receiving surgical, radiotherapy,
or other treatment [the Initiative for Early Lung Cancer
Research on Treatment (IELCART)] was started (17) in
order to assess treatment differences in the course of clinical
care by documenting the QoL measures before and after
surgery to identify critical time points at which supportive
interventions (e.g., additional social support, physical
therapy) would be most helpful.
The current study aims to build on our previous work (10)
by assessing the differential impact of the extent of
surgical resection (SL vs. L) among VATS on QoL using
longitudinal IELCART data in order to identify critical
post-operative time points at which QoL significantly
changes for each resection method.
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Methods
We reviewed all patients enrolled in the prospective cohort
study, IELCART since its start in 2016 who underwent
VATS surgery for NSCLC, by the extent of surgery (SL or
L). Sublobar resection included segmentectomy and wedge
resection. We included all patients with a first primary
NSCLC had pathologic Stage IA (T1a-1cN0M0) NSCLC
(8th AJCC/UICC staging) (18) who did not receive adjuvant
chemotherapy, radiation therapy, or subsequent surgery
within 12 months of the initial surgery. This study was
conducted in accordance with the Declaration of Helsinki
and was approved by the Institutional Review Board of
Mount Sinai Hospital (IRB# IF 2365016). At enrollment,
HIPAA-compliant written informed consent was obtained
from all participants.
Demographic, comorbidities, social support, pre-surgical
CT findings, and post-surgical pathologic findings were
documented. Clinical TNM staging was obtained for all
participants, and pre-operative diagnosis, if available, was
also recorded. Pre-surgical QoL scores were obtained by
in-person interviews during the patient’s pre-surgical clinic
visit. If that was not possible, telephone interviews were
performed or the questionnaires were completed by the
patients and returned via mail. Follow-up QoL scores were
obtained at clinic visits within 4, 6, and 12 months after
surgery.
Sociodemographic and medical characteristics
Prior to surgery, at the time of IELCART enrollment,
baseline demographic data, smoking history, and 12
different comorbidities—presence of additional cancers,
asthma, emphysema or chronic obstructive pulmonary
disease, high blood pressure, high cholesterol, angioplasty
or stent, myocardial infarction, stroke, peripheral vascular
disease, liver disease, diabetes, and kidney disease—
were collected on each patient. A comorbidity score
was calculated by totaling the number of documented
comorbidities for each patient, ranging from 0 to 12. Height
and weight were documented and body mass index (BMI)
was calculated in kilograms per meters squared (kg/m2);
obesity was defined as a BMI ≥30 kg/m2.
Social support as perceived by each patient was
documented at baseline enrollment using the Medical
Outcomes Study Social Support Survey (MOS index)
consisting of a 19-item questionnaire. Its five subscales are:
emotional/informational support, tangible support, positive
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interaction, affection, and whether there is someone to help
keep one’s mind off things (19). The overall MOS index
score ranges from 0–100 with a higher score corresponding
to better patient-perceived social support.
The tumor consistency on the pre-surgical CT scan
was documented as solid, part-solid, or nonsolid (20). The
post-surgical pathology results of the tumor cell-type and
maximum diameter were documented for each patient.
Quality of life instruments
Physical Component Summary (PCS) and Mental
Component Summary (MCS)
The 12-item Short Form (SF-12v2), a shorter version
of SF-36v2 (21), is used to calculate two norm-based
component scores, the PCS score and a MCS score.
These two component scores are calculated using different
standardized weighted summaries of eight domains of
health: physical functioning, role limitations due to physical
health, bodily pain, general health perceptions, vitality,
social functioning, role limitations due to emotional
problems, and mental health within the previous 4 weeks.
For PCS, the four physical subscales have a more significant
weight while for MCS, the four mental health subscales
have more weight. The norm-based average for the United
States population is a mean of 50 and standard deviation
(SD) of 10 for both PCS and MCS; higher scores reflect
better physical and mental health. A minimum of a 3-point
difference has been suggested as a clinically important
difference or change for both scores (21).
Functional Assessment of Cancer Therapy-Lung
Cancer (FACT-LCS)
FACT-L is a multi-dimensional validated self-report
instrument to document symptoms of different cancers (22).
We used only the lung cancer subscale (LCS) which asks
about symptoms of dyspnea, weight loss, mental clarity,
coughing, appetite, tightness in the chest, and difficulty
breathing within the previous 7 days. The FACT-LCS
scores range from 0–28; a higher score means there are
fewer symptoms. A 2- to 3-point difference has been
suggested as being clinically meaningful (23).
The Patient Health Questionnaire-4 (PHQ-4)
The Patient Health Questionnaire-4 (PHQ-4) is composed
of two subscores, GAD-2 and PHQ-2, each of which have
two questions. The two-item GAD-2 Anxiety measure,
drawn from the GAD-7 instrument (24), is obtained by
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Table 1 Average QoL scores and standard deviation (SD) for patients undergoing sublobar resection (SL) and lobectomy (L) at baseline (T0) and
three postoperative time categories. Missing data for each time category are also given
Average QoL score (SD) by time categories

T0 (n=119)

T1–T4 (n=172)

T5–T8 (n=172)

T9–T15 (n=144)

Sublobar

46.9 (10.3)

44.0 (10.5)

47.1 (8.5)

47.7 (9.3)

Lobectomy

48.6 (9.9)

39.8 (10.5)

45.9 (10.4)

47.4 (10.7)

Sublobar

51.6 (10.7)

51.2 (11.0)

52.3 (10.2)

52.9 (11.2)

Lobectomy

52.2 (7.9)

53.9 (10.2)

54.3 (8.8)

54.4 (7.3)

Sublobar

23.4 (3.5)

22.6 (4.4)

24.4 (3.8)

24.3 (4.5)

Lobectomy

24.0 (4.2)

22.2 (3.8)

24.1 (3.6)

24.2 (3.5)

Sublobar

1.9 (1.9)

1.2 (1.6)

1.1 (1.6)

1.1 (1.4)

Lobectomy

2.2 (2.0)

1.0 (1.6)

1.1 (1.7)

0.8 (1.6)

Sublobar

0.9 (1.5)

1.0 (1.6)

0.9 (1.5)

0.7 (1.4)

Lobectomy

0.7 (1.2)

0.8 (1.5)

1.0 (1.7)

0.5 (1.2)

Sublobar

59 (49%)

23 (19%)

15 (12%)

29 (24%)

Lobectomy

22 (31%)

9 (13%)

7 (10%)

20 (29%)

PCS

MCS

FACT-LCS

GAD-2

PHQ-2

Missing data*

* Missing data indicates the number of subjects who did not complete the QoL questionnaire at each time period. Percentage out of total
of subjects with missing data during each time periods. PCS, Physical component summary; MCS, mental component summary; FACTLCS, Functional Assessment of Cancer Therapy-Lung Cancer; GAD, general anxiety disorder; PHQ, Patient Health Questionnaire-4.

adding the scores for two items. Possible scores range from
0–6, where lower scores correspond to less anxiety. A GAD-2
score of 3 or higher is the preferred cut-off for identifying
patients with generalized anxiety disorder (25).
The two-item PHQ-2 Depression measure is drawn
from the PHQ-9 instrument. The PHQ-2 score is obtained
by adding the scores for the two items. Possible scores
range from 0–6, where lower scores correspond to fewer
symptoms of depression (24). A PHQ-2 score of 3 or higher
is optimal cut-off score for clinical depression (26).
Statistical analyses
Results were summarized by means (SD) or medians
(interquartile range, IQR) for continuous and ordinal
data, and frequencies and percentages for categorical data.
Comparison of SL and L patients, for continuous variables
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used two-sample t-tests for normally distributed variables,
otherwise the Mann-U Whitney rank test was used. For
categorical variables, Pearson’s χ2 test (or Fisher’s exact test
where appropriate) was used.
The average score for each QoL measure (PCS, MCS,
FACT-LCS, GAD-2, and PHQ-2) was calculated before
treatment (T0), and for each postoperative month. The
QoL postoperative scores were initially categorized into
the following three time categories: (I) T1–T4 if the
information was obtained within the first four postoperative
months, (II) T5–T8 if obtained within 5 to 8 postoperative
months, and (III) T9–T15 if obtained within 9 to 15
postoperative months, separately for SL and L (Table 1).
Analyses of missing data were performed separately for
patients who had two or more consecutive missing QoL
scores up to and including the 12-month evaluation (due to
loss to follow-up), and for patients with intermittent missing
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Figure 1 Scatter plot of PCS scores with non-parametrically
smoothed LOWESS curves by surgical group using 80% of
the data closest to each time point (span =0.8). PCS, physical
component summary.

QoL scores. Differences in the missing data patterns were
assessed between surgical groups (27).
To explore critical time points when the trajectory
of QoL scores shift, we first used nonparametric locally
weighted smoothing (LOWESS) to fit a continuous curve
across the time points when the data were collected. The
LOWESS smoother was estimated by starting with the
first time period, using 80% of the data closest to each
time point (i.e., span =0.8) (Figure 1 provides an example
for PCS). This plot allows for visualization of QoL trends
and identification of times when an upward or downward
shift of the QoL scores occurs (28). For PCS scores, the
best interval knot for the change in the trajectory was
at 2 months. LOWESS plots were made for the other
QoL scores and these also pointed to an interval knot at
2 months.
To capture linear trends in QoL using time as a
continuous variable, we developed a piecewise linear
mixed effects model to estimate each of the QoL measures
at baseline and throughout the postoperative period.
Correlations between scores for each patient were
accounted for by specifying a random intercept. This
model posits that patients vary in baseline QoL scores
and have different patient-specific trajectories during the
post-operative 12-month time. Moreover, it allows us
to characterize critical point(s) in time when the linear
trajectory of the QoL measure changes (28-30). Using
this model, the extent of surgery (SL or L) for any QoL
measure can be estimated by averaging over patientspecific trajectories by surgical group membership. The
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model provides a more robust and flexible approach than
a repeated measures analysis of variance model, because
the usage of pre-defined time categories is not required
and because the model better accommodates missing or
mistimed QoL outcome measurements (29). We estimated
two separate rates of change for each QoL measure; the
first rate from time =0 (baseline) to 2 months after surgery,
and the second rate from 2.1 to 12 months after surgery.
In addition to including the piecewise time effects, the
surgery (SL vs. L), and the interaction of time and extent
of surgery, each QoL model included the effects of sex,
race, post-secondary education, age, BMI, pack-years, the
baseline MOS index, maximum pathologic tumor size, and
comorbidity ordinal score as specified below:
E(Scoreij)=β1+ β2Timeij+β3(Timeij – t*)+ + β4Surgery_extenti+
β5TimeijxSurgery_extenti+β6(Timeij–t*)+ xSurgery_extenti+
β7Sexi+β8Racei+β9Collegei+β10Agei(centered)+β11BMIi(centered)+
β12Packyrsi(centered)+β13MOSi(centered)+β14Tumor_sizei(centered)+
β15Comorbidity_scorei(centered), [1]
with t*=2 months, (Timeij –t*)+ is equal to (Timeij –2) when
Timeij >2 and equal to zero when Timeij ≤2. When expressed
in terms of average response prior to or after t*=2 months,
the final model for patients in the L group (Surgery_
extenti=0), for example, would be:
E(Scoreij)=β1+ β2Timeij +..+βpXp, when Timeij ≤ t*; [2]
E(Scoreij)=(β1 - β3t*)+(β2 +β3)Timeij +..+βpXp, when Timeij >t* [3]
Thus the rate of change for time prior to 2 months was
estimated by β2, and subsequent to 2 months the rate of
change was estimated by (β2+β3). The fit of the final model
for each of the QoL measures was assessed by evaluating
the normality of the scaled residuals.
The final model(s) used covariate values (e.g., age, sex)
to estimate the QoL score for each of the QoL measures
at baseline (time =0) and at the postoperative times of 2,
6 and 12 months; for continuous covariates, the sample
averages were used and the categorical covariates, the
most representative subgroup was used. Each estimate was
calculated separately for the SL and L patients. This model
also allowed for assessing whether QoL measures differed
among the covariates. All statistical analyses were performed
using SAS Software version 9.4 and R version 3.5.2.
Results
Of the 201 participants included in this study, sublobar
resection (SL) was performed more frequently than
lobectomy (L) [127 (63.2%) vs. 74 (36.8%), P<0.001]. Table 2
shows that at baseline (T0), no significant differences were
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Table 2 Patient sociodemographic and medical characteristics by extent of surgery
Patient characteristics

Sublobar resection (n=127)

Lobectomy (n=74)

Total (N=201)

P value

70 (12)

66 (12.5)

69 (13)

0.14

Female

83 (65.4)

50 (67.6)

133 (66.2)

0.75

Male

44 (34.6)

24 (32.4)

68 (33.8)

Asian

11 (8.7)

10 (13.5)

21 (10.4)

Black/African American

21 (16.5)

11 (14.9)

32 (15.9)

Other

18 (14.2)

6 (8.1)

24 (11.9)

White Non-Hispanic

77 (60.6)

47 (63.5)

124 (61.7)

66 (54.5)

37 (55.2)

103 (54.8)

0.93

33 (27.7)

19 (27.9)

52 (27.8)

0.98

26.4 (7.35)

25.4 (7.75)

25.8 (7.4)

0.51

15 (34.925)

15 (43)

15 (37.6)

0.92

Current smoker

13 (10.3)

5 (6.8)

18 (9.0)

0.27

Former smoker

83 (65.9)

44 (59.5)

127 (63.5)

Never smoker

30 (23.8)

25 (33.8)

55 (27.5)

2 (2)

2 (3)

2 (2)

0.13

0.6 (0.7)

0.4 (0.7)

0.5 (0.7)

0.46

96.8 (14.0)

97.4 (14.2)

96.8 (13.9)

0.85

Solid

92 (72.4)

59 (79.7)

151 (75.1)

0.36

Part-solid

25 (19.7)

14 (18.9)

39 (19.4)

Nonsolid

10 (7.9)

1 (1.4)

11 (5.5)

Age (year)
Median (IQR)
Sex (%)

Race (%)
0.45

College degree (%)
Yes
2

BMI ≥30 kg/m (%)
Yes
2

BMI (kg/m )
Median (IQR)
Pack-years
Median (IQR)
Smoking status (%)

Comorbidity ordinal score
Median (IQR)
Time from baseline QoL to surgery date (months)
Median (IQR)
Social support (MOS index)
Median (IQR)
Tumor consistency on pre-surgical CT (%)

Post-operative pathology
Histology
Adenocarcinoma

102 (80.3)

60 (81.1)

162 (80.6)

Other

11 (8.7)

9 (12.2)

20 (10.0)

Squamous cell

14 (11.0)

5 (6.8)

19 (9.5)

15 (7.5)

20 (9.75)

15 (8.0)

0.48

Max. pathologic tumor diameter (mm)
Median (IQR)
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Table 3 Estimated QoL scores using the adjusted linear piecewise mixed effects model and estimated rate of change, separately for sublobar
resection and lobectomy patients
QoL measures

Baseline estimated
score

Per month rate (within
Per month rate
2 months post-operative) (2.1–12 months post-operative)

Estimate SE P valuea Estimate SE

P valueb

Estimate

SE

P valuec

12-month estimated score
Estimate SE

P valued

PCS (SF-12)
Sublobar

46.34

1.20

–

−0.18

0.59

0.76

0.29

0.14

0.04

48.88

1.24

0.02

Lobectomy

46.01

1.30

–

−2.30

0.68

0.0009

0.74

0.19

<0.0001

48.79

1.49

0.05

Sublobar - Lobectomy

0.33

1.51

0.83

2.12

0.90

0.02

−0.45

0.23

0.06

–

–

–

Sublobar

52.50

1.12

–

−0.04

0.56

0.94

0.11

0.13

0.40

53.54

1.16

0.32

Lobectomy

53.89

1.21

–

0.72

0.65

0.27

−0.04

0.18

0.80

54.87

1.40

0.46

Sublobar - Lobectomy

−1.39

1.41

0.33

−0.76

0.86

0.38

0.16

0.22

0.48

–

–

–

Sublobar

23.85

0.45

–

0.06

0.22

0.79

0.11

0.05

0.03

25.07

0.46

0.003

Lobectomy

24.26

0.49

–

−0.40

0.26

0.12

0.16

0.07
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, P values test rates of change vs. 0 (no change) within each group, and between surgical groups; , P values test differences in
estimated 12 months scores vs. baseline scores within surgical group.

found between the SL and L patients as to age, sex, other
sociodemographic or medical characteristics, except that the
median tumor size on pathology was significantly smaller
for SL than L patients (14 vs. 20 mm, P<0.001). Median
MOS index scores on the baseline were not statistically
significantly different.
The average PCS score at baseline were 46.34 and 46.01,
P=0.83, respectively, for SL and L patients (Table 3, Figure 2A).
The average PCS scores for SL and L patients were
below the average of the general population (mean ± SD:
50±10). For both SL and L patients, PCS scores decreased
in the first two postoperative months, but the decrease
was less severe for SL than for the L patients [−0.18 vs.
−2.30, P=0.02]. PCS scores increased in the subsequent 10
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postoperative months for both SL and L, but the monthly
rate of increase for SL patients was slower than that for L
patients [+0.29 vs. +0.74, P=0.06]. The average PCS score at
12 months was significantly higher than the average baseline
PCS score for SL patients (48.88 vs. 46.34, difference
=+2.55 or rounded to 3, P=0.02) and for L patients (48.79
vs. 46.01, difference =+2.78 or rounded to 3, P=0.048).
Overall, the average physical health score for both SL and L
patients started and remained below the general population
average, both decreased significantly in the first two months
after surgery, but significantly improved by 3 points by the
end of the first postoperative year.
Average MCS scores at baseline for SL and L patients
were 52.50 vs. 53.89, P=0.33. The average scores were
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Figure 2 Average estimated score trajectories using the adjusted linear piecewise mixed effects model at times =0, 2, 6 and 12 months for
each of the quality of life measures, separately for sublobar and lobectomy patients. (A) SF-12: PCS and MCS score trajectories. For the
United States general population, the average is 50 and standard deviation 10; (B) FACT-LCS (lung cancer symptoms) score trajectories;
(C) PHQ-4: GAD-2 anxiety and PHQ-2 depression score. Patients with scores of 3 or more are considered to be sufficiently severe to have
further diagnostic evaluation (25,26).

slightly above that of the general population (Figure 2A).
Within the first two postoperative months, MCS scores did
not significantly change for either SL or L patients [−0.04
vs. +0.72, P=0.38] nor for the subsequent 10 postoperative
months [+0.11 vs. −0.04, P=0.48]. In fact, the monthly
rates of change were not significantly different for SL and
L patients during the entire first post-operative year. At
12 months, the average MCS was not significantly higher
than the average baseline MCS for SL patients (53.89 vs.
52.54, difference =1.35; rounded to 1, P=0.32) or for L
patients (54.87 vs. 53.89, difference =+0.98; rounded to 1,
P=0.46). Overall, the average mental health score for both
SL and L patients was above the general population average
prior to surgery, improved by one point at the end of the
first operative year.
The average FACT-LCS symptom scores at baseline for
SL and L patients were 23.85 vs. 24.26, P=0.47 (Figure 2B).
FACT-LCS scores increased, showing an improvement in
symptoms, and did not significantly differ between SL and
L patients during the first two postoperative months [+0.06
© Journal of Thoracic Disease. All rights reserved.

vs. −0.40, P=0.17]. During the subsequent 10 postsurgical
months, FACT-LCS scores continued to increase at similar
rates for both SL and L patients [+0.11 vs. +0.16, P=0.58]. By
12 months, the average FACT-LCS score had significantly
improved over the average baseline score for SL patients
[25.08 vs. 23.85, difference =+1.23, P=0.003], but not for L
patients [25.02 vs. 24.26, difference =+0.79, P=0.13].
The average GAD-2 anxiety scores at baseline for SL
and L were 1.69 vs. 1.88, P=0.43 (Figure 2C). The scores
significantly decreased for both SL and L patients during
the first 2 postoperative months [−0.29, P=0.002 vs. −0.49,
P<0.0001], showing a decrease in anxiety; the rates of
decrease per month were similar for both SL and L patients
(P=0.18). No further changes were observed for the next 10
postoperative months (0.00 vs. +0.01, P=0.78). The average
GAD-2 scores at 12 months were significantly lower than
the average baseline scores for SL patients [1.14 vs. 1.69,
difference =−0.85 or rounded to 1, P=0.0002] and for L
patients [1.04 vs. 1.88, difference =−0.58 or rounded to
1, P=0.001], showing that anxiety had decreased over the
J Thorac Dis 2020;12(7):3488-3499 | http://dx.doi.org/10.21037/jtd-20-402
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operative year for both SL and L patients.
The average PHQ-2 depression scores at baseline for SL
and L were 0.74 and 0.60, P=0.50 (Figure 2C). The scores
increased slightly for the first 2 postsurgical months for
both SL and L patients [+0.04 vs. +0.08, P=0.72], suggesting
increasing depression, and then improved over the
remaining 10 postoperative months [−0.01 vs. −0.02, P=0.75].
The average PHQ-2 score at 12 months was lower than the
average baseline scores for both SL and L patients [0.67 vs.
0.74, difference =−0.07, P=0.64] and [0.52 vs. 0.60, difference
=−0.08, P=0.67]. Overall, depression scores had improved, but
not significantly over the course of first postoperative year.
For all QoL measures, the average physical health,
mental health, and lung cancer symptom scores were lower
for women than for men. The FACT-LCS was significantly
lower (P=0.003) by 1.58 points, rounded to 2 for women
across all time points. The anxiety and depression scores
were worse for women than for men, but only the anxiety
GAD-2 score was significantly higher (P=0.04) by 0.39
points across all time points (P=0.04).
Older patients had significantly related to better mental
health (MCS, P<0.001), and also lower anxiety (GAD-2,
P<0.001) and depression (PHQ-4, P<0.001) scores.
Having a post-secondary school degree was associated with
significantly lower lung cancer symptom scores (FACTLCS, P=0.009). More comorbidities was significantly
related to lower physical health (PCS, P=0.01), increased
symptoms (i.e., lower FACT-LCS, P=0.01), and higher
depression symptoms (PHQ-2, P=0.05). Perceived social
support prior to surgery as given by the MOS score was
significantly related to better scores for all QoL measures.
Analyses of missing data
Analyses of missing data were performed separately for
patients who had two or more consecutive missing QoL
scores up to and including the 12-month evaluation (due
to loss to follow-up), and for patients with intermittent
missing QoL scores. Ten patients were loss-to-follow-up
up during the study period; two of them withdrew their
consent, one relocated, and the remaining 7 missed followup appointments and could not be reached by telephone.
No significant difference in the number of loss-to-followups was found between SL and L patients [6 (60%) vs. 4
(40%), P=0.75] within this group.
For patients with intermittent missing data (Table 1), a
longitudinal logistic regression model was used to compare
missingness patterns between SL and L by creating a binary
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variable (rij=1 if the QoL observation was missing; rij=0 if
it was obtained) as the dependent variable in a marginal
model using generalized estimating equations. The
predictor variables included categorical time for the missing
observation (with T0 as the reference), extent of surgery
(SL or L), and the interactions of categorical time and
extent of surgery. The global chi-squared (χ2) test showed
no significant differences in the likelihood of missing data
between the SL and L patients, nor in the interaction of
time and surgical groups [Surgery extent: χ12 =1.62, P=0.20;
Surgery extent x time: χ 32 =5.05, P=0.17]. The results of
these analyses supported that patterns for loss-to-follow-up
and intermittent missing data were similar between surgical
groups. Therefore, in this study the missing data patterns
themselves may not lead to serious biases in the estimation
of surgical differences in QoL over time (27).
Discussion
Physical health (PCS) scores decreased within the first
two postoperative months for both SL and L patients,
and significantly more for L patients. Over the remaining
10 months, both SL and L patients rebounded significantly.
While no significant changes were detected in lung cancer
symptom (FACT-LCS) scores during the first two months
for either group, SL patients reported significantly better
scores a year after surgery compared to baseline while
L patients did not. Mental health summary (MCS) and
depression (PHQ-2) scores remained stable throughout
the postoperative 12-month period. GAD-2 anxiety scores
decreased significantly in the first two postoperative
months in both groups, and remained stable thereafter. The
12-month scores for PCS and GAD-2 were significantly
better than the baseline scores for both SL and L patients.
This study is the first to examine changes in multiple
validated measures of QoL among early stage NSCLC
surgical patients in a longitudinal prospective design which
allowed for identification of critical postoperative changes
in patient-specific trajectories during the first postoperative
year. It revealed that interventions to improve physical QoL
particularly during the first two postsurgical months might
be most important as the lowest PCS score was observed
during that time period for both SL and L patients. The
physical score findings are consistent with those of our
previous study (9) which also showed a decrease in physical
health after surgery. The current study, however, allowed
us to pinpoint a time period when intervention might be
particularly beneficial—the first two postoperative months.

J Thorac Dis 2020;12(7):3488-3499 | http://dx.doi.org/10.21037/jtd-20-402

Journal of Thoracic Disease, Vol 12, No 7 July 2020

We confirmed that L patients fared worse in terms of
PCS as compared with SL patients, a difference previously
identified (9). Cancer-related symptoms, as measured
by FACT-LCS, worsened slightly for L patients while
improving slightly for SL patients; although these differences
were not statistically significant. These QoL findings
point to particular needs among L patients regarding pain
management and physical functioning early in their recovery.
Furthermore, the short-term negative impact on QoL of
L patients should also be recognized when making surgical
treatment decisions and in post-surgical management.
Unlike the other QoL measures, anxiety appeared to
significantly improve within the first two postoperative
months, and then stabilized over time. We speculate that
the removal of the malignancy caused relief as compared
with pre-surgical worries regarding morbidity and mortality
related to the surgery and its efficacy. Other aspects of
mental health, such as stigma and isolation were not assessed
within the context of the current study, but have appeared
as important considerations in qualitative analyses (7),
and should be considered in the future. Also, it is possible
that certain subgroups of early stage lung cancer surgical
patients, such as those with pre-existing mental health
diagnoses, exhibit lower QoL after surgery. Such patients
might benefit from stronger postsurgical mental health
intervention, as postsurgical QoL has been found to be
lower among early stage patients who have higher presurgical depression and anxiety scores (14,16).
We also found significant differences between women
and men for lung cancer symptoms (FACT-LCS) and anxiety
(GAD-2) scores. Such sex-related differences were also
identified in the focus groups (7) and need to be considered
in postsurgical care. Although social support did not differ
between SL and L patients at baseline, more perceived
social support was a significant factor for all QoL measures
used in this report. The literature indicates that social
support as well as psychosocial and behavioral supportive
interventions can have positive impact on post-surgical QoL
(31,32). Thus, future research should consider whether
social support could potentially be an effect modifier of
the impact of extent of surgery so that the impact on QoL
of more invasive surgery could be attenuated by increased
social support.
A limitation of this report is missing data at baseline,
which raises concerns about the validity of the average QoL
differences and degree of relative change. Postoperative
recruitment of patients accounted for 32% of the
missing baseline QoL data, but these percentages did not
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significantly differ between SL and L patients (P=0.34).
As patients had just received a diagnosis of lung cancer,
reasons for failure to collect baseline data included patients
having another appointment, needing to complete critical
actions given this life-threatening diagnosis, personal hesitation,
and nervousness. Many, however, agreed to participate after
their treatment. Systematic differences by extent of surgery
received would not be anticipated, given these considerations.
Adjustment for multiple comparisons was not performed as
this is our first exploratory study to compare the impact of
SL and L on QoL using the IELCART database, this could
lead to inflation of the Type I error rate. A subsequent study
with preplanned hypotheses will be conducted to confirm our
observed association as data accrued. Additional limitations
include the possibility of residual confounding.
In conclusion, the current analyses support the idea
of a critical postoperative window of two months where
interventions could potentially improve physical health
further. Treatments such as mind-body interventions that
target pain and general mental health (e.g., relaxation,
biofeedback) could be offered to patients, particularly
lobectomy patients, who are experiencing symptoms. Such
interventions have found to be effective in managing other
chronic illnesses (33-36) and could be readily applied to early
stage lung cancer surgical patients in an effort to improve
overall QoL among this growing patient population.
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